47,140 Shares in CEL-SCI Co. (NYSE:CVM) Acquired by Calton & Associates Inc.

Calton & Associates Inc. acquired a new position in CEL-SCI Co. (NYSE:CVM) during the third quarter, HoldingsChannel.com reports. The fund acquired 47,140 shares of the company’s stock, valued at approximately $50,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Tidal Investments LLC bought a new stake in CEL-SCI during the 1st quarter worth approximately $27,000. Chilton Capital Management LLC raised its stake in CEL-SCI by 297.4% during the 1st quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock worth $31,000 after acquiring an additional 12,200 shares during the period. Black Diamond Financial LLC raised its stake in CEL-SCI by 35.8% during the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the period. Cutter & CO Brokerage Inc. raised its stake in CEL-SCI by 29.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after acquiring an additional 24,634 shares during the period. Finally, Thoroughbred Financial Services LLC raised its stake in CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares during the period. Hedge funds and other institutional investors own 12.08% of the company’s stock.

CEL-SCI Price Performance

NYSE CVM opened at $0.90 on Thursday. CEL-SCI Co. has a 12 month low of $0.89 and a 12 month high of $3.23. The stock has a market cap of $48.98 million, a price-to-earnings ratio of -1.44 and a beta of 0.65. The company’s 50 day moving average is $1.07 and its two-hundred day moving average is $1.24. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00.

CEL-SCI (NYSE:CVM) last released its earnings results on Thursday, August 15th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, research analysts anticipate that CEL-SCI Co. will post -0.52 earnings per share for the current year.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.